Joon Lee
Stock Analyst at Truist Financial
(4.97)
# 86
Out of 4,604 analysts
518
Total ratings
57.6%
Success rate
36.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joon Lee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VYGR Voyager Therapeutics | Maintained: Buy | n/a | $3.13 | - | 16 | Mar 17, 2026 | |
| EDIT Editas Medicine | Maintained: Hold | n/a | $2.77 | - | 22 | Mar 17, 2026 | |
| SLDB Solid Biosciences | Maintained: Buy | n/a | $8.62 | - | 11 | Mar 13, 2026 | |
| PRAX Praxis Precision Medicines | Reiterated: Buy | $700 | $310.07 | +125.76% | 29 | Mar 12, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintained: Buy | $525 | $478.71 | +9.67% | 16 | Mar 11, 2026 | |
| ANAB AnaptysBio | Maintained: Hold | $50 | $55.13 | -9.31% | 30 | Mar 9, 2026 | |
| VKTX Viking Therapeutics | Maintained: Buy | n/a | $32.94 | - | 43 | Mar 5, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintained: Buy | n/a | $60.72 | - | 14 | Mar 3, 2026 | |
| CORT Corcept Therapeutics | Maintained: Buy | n/a | $109.80 | - | 38 | Mar 2, 2026 | |
| NTLA Intellia Therapeutics | Maintained: Buy | n/a | $11.32 | - | 29 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $53.07 | - | 24 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $69.10 | - | 11 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $6.00 | - | 41 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $49.67 | - | 3 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $261.62 | - | 26 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $212.17 | - | 37 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $90 → $76 | $25.81 | +194.46% | 29 | Feb 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $42.20 | - | 2 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $4.11 | - | 8 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $6.20 | - | 24 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $844.50 | n/a | 38 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $10.25 | n/a | 1 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $18 | $7.52 | n/a | 10 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $100 → $65 | $9.00 | n/a | 5 | Jan 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $7 → $4 | $5.47 | n/a | 4 | Dec 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 | $3.51 | n/a | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $18.43 | n/a | 1 | Aug 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $76 | $43.68 | n/a | 1 | Jun 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $20 | $6.82 | n/a | 1 | Jun 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $16.39 | n/a | 1 | Aug 8, 2014 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $33 | $27.15 | n/a | 1 | Aug 7, 2014 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $14 | $1.36 | n/a | 1 | Jul 28, 2014 |
Voyager Therapeutics
Mar 17, 2026
Maintained: Buy
Price Target: n/a
Current: $3.13
Upside: -
Editas Medicine
Mar 17, 2026
Maintained: Hold
Price Target: n/a
Current: $2.77
Upside: -
Solid Biosciences
Mar 13, 2026
Maintained: Buy
Price Target: n/a
Current: $8.62
Upside: -
Praxis Precision Medicines
Mar 12, 2026
Reiterated: Buy
Price Target: $700
Current: $310.07
Upside: +125.76%
Vertex Pharmaceuticals
Mar 11, 2026
Maintained: Buy
Price Target: $525
Current: $478.71
Upside: +9.67%
AnaptysBio
Mar 9, 2026
Maintained: Hold
Price Target: $50
Current: $55.13
Upside: -9.31%
Viking Therapeutics
Mar 5, 2026
Maintained: Buy
Price Target: n/a
Current: $32.94
Upside: -
BioMarin Pharmaceutical
Mar 3, 2026
Maintained: Buy
Price Target: n/a
Current: $60.72
Upside: -
Corcept Therapeutics
Mar 2, 2026
Maintained: Buy
Price Target: n/a
Current: $109.80
Upside: -
Intellia Therapeutics
Mar 2, 2026
Maintained: Buy
Price Target: n/a
Current: $11.32
Upside: -
Mar 2, 2026
Maintained: Buy
Price Target: n/a
Current: $53.07
Upside: -
Feb 27, 2026
Maintained: Buy
Price Target: n/a
Current: $69.10
Upside: -
Feb 27, 2026
Reiterated: Buy
Price Target: n/a
Current: $6.00
Upside: -
Feb 26, 2026
Maintained: Buy
Price Target: n/a
Current: $49.67
Upside: -
Feb 25, 2026
Maintained: Buy
Price Target: n/a
Current: $261.62
Upside: -
Feb 24, 2026
Maintained: Buy
Price Target: n/a
Current: $212.17
Upside: -
Feb 13, 2026
Maintained: Buy
Price Target: $90 → $76
Current: $25.81
Upside: +194.46%
Nov 10, 2025
Maintained: Buy
Price Target: n/a
Current: $42.20
Upside: -
Nov 6, 2025
Maintained: Buy
Price Target: n/a
Current: $4.11
Upside: -
Nov 5, 2025
Maintained: Buy
Price Target: n/a
Current: $6.20
Upside: -
Aug 1, 2025
Maintained: Buy
Price Target: n/a
Current: $844.50
Upside: n/a
Dec 4, 2024
Rated: Buy
Price Target: n/a
Current: $10.25
Upside: n/a
Nov 14, 2023
Maintained: Buy
Price Target: $18
Current: $7.52
Upside: n/a
Jan 17, 2023
Maintained: Buy
Price Target: $100 → $65
Current: $9.00
Upside: n/a
Dec 8, 2022
Maintained: Hold
Price Target: $7 → $4
Current: $5.47
Upside: n/a
May 5, 2022
Reiterated: Buy
Price Target: $14
Current: $3.51
Upside: n/a
Aug 8, 2019
Maintained: Buy
Price Target: $10
Current: $18.43
Upside: n/a
Jun 19, 2019
Initiated Coverage: Buy
Price Target: $76
Current: $43.68
Upside: n/a
Jun 19, 2019
Initiated Coverage: Buy
Price Target: $20
Current: $6.82
Upside: n/a
Aug 8, 2014
Maintained: Buy
Price Target: n/a
Current: $16.39
Upside: n/a
Aug 7, 2014
Reiterated: Buy
Price Target: $33
Current: $27.15
Upside: n/a
Jul 28, 2014
Maintained: Buy
Price Target: $14
Current: $1.36
Upside: n/a